BIOCORP Signs Two New Partnerships With Mallya Technology
17.2.2021 10:00:00 EET | Business Wire | Press release
Regulatory News:
BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development and manufacturing of innovative medical devices, today announces the signature of new partnerships with Health2Sync and SocialDiabetes, companies headquartered in Taiwan and Spain, respectively.
These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.
In detail, the platform developed by SocialDiabetes (CE marked and FDA 510K) allows self-monitoring of insulin doses and offers personalized recommendations to patients. All of the data collected feeds a telemedicine platform using augmented intelligence for physicians and specialized call centers. To date, this platform is used by 250,000 patients with diabetes, mainly in Spain, Mexico, Colombia and Chile.
Health2Sync’s app, through its analytics engine, provides personalized recommendations and nudges concerning meals, exercise, and blood glucose management, delivered in a compelling way that encourages users to stay adherent to treatment plans. Health2Sync’s Patient Management Platform utilizes decision support modules for healthcare providers to deliver effective interventions that are also scalable, with insulin dosing as an example. The patient management platform is deployed in over 260 of diabetes care institutions in Taiwan, Malaysia and Japan, and the mobile app is used by more than 600,000 patients in Taiwan, Japan, USA, Hong Kong, Malaysia, Singapore and Australia.
Patients using these digital solutions will be able to automatically synchronize the data recorded by their Mallya sensor, thus benefiting from a complete monitoring offer combining glycemic data analysis and insulin dose feedback. This information can be transmitted in real time to treating physicians via a devoted portal to improve the quality of dialogue with patients, optimize treatment plans and offer personalized recommendations.
Éric Dessertenne, CEO of BIOCORP, explained: “These new partnerships come at a time when our teams are preparing for the large-scale commercial launch of Mallya, which is already compatible with almost all disposable pens on the market. Its integration with the most widely used applications in local markets is a great advantage for the rapid adoption of Mallya in these countries. Health2Sync and SocialDiabetes will enable us to accelerate our penetration in Asia and some Latin American countries, geographical areas where the diabetic population and the use of connected medicine are highly developed".
”Health2Sync bridges the lengthy gap between doctor visits by enabling frequent digital touch points between patients and healthcare providers. Insulin dosing data captured by Mallya will significantly enhance the experience of patients on insulin “said Ed Deng, Co-Founder and CEO of Health2Sync. “We expect better adherence and improved outcomes that come as a result of making data available to patients and healthcare providers.”
“We are thrilled to initiate this agreement with Biocorp. Mallya sensor is a world-class player and represents the type of high-quality technology we want to bring to our customers. Patients increasingly demand combined solutions that provide them with high connectivity and data driven personalized support. This alliance with Biocorp is a big step toward the digital health ecosystem the market is waiting for. “said María Jesús Salido, cofounder & CEO of Social Diabetes.
ABOUT HEALTH2SYNC
Founded in 2013, Health2Sync provides a comprehensive health-management platform for people with chronic conditions. Its products combine mobile, cloud, and data analytics, enabling patients to obtain personalized care and allows care providers and family to care for patients remotely. With the largest network of clinics and hospitals, it is the leading solution in Asia that brings an effective, yet scalable solution to diabetes management.
For more information, please visit https://www.health2sync.com
ABOUT SOCIAL DIABETES
SocialDiabetes is set to become one of the best solutions to foster the digital management of diabetes. Leader in Spanish speaking markets, the company, headquartered in Barcelona with offices in the UK, and Ciudad de Mexico was first created to meet the needs of Victor Bautista, a Type 1 diabetes patient and current CTO & co-founder. A company of patients working for patients, SocialDiabetes provides a system that synchronizes with multiple devices, easily connect patients with the healthcare professionals that are treating them and provides relevant information for decision making in one place.
For more information, please visit www.socialdiabetes.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005923/en/
Contact information
BIOCORP
Jacques Gardette
Chairman of the Board
investisseurs@biocorp.fr
Éric Dessertenne
Chief Executive Officer
Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
ULYSSE COMMUNICATION
Bruno Arabian
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
Nicolas Daniels
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 03:00:00 EEST | Press release
Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed
Vertex Announces US FDA Approval for Expanded Use of CASGEVY ® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 02:58:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform the future for people living with sickle cell disease and transfusion-dependent beta thalassemia. The remarkable consistency of results across age groups reinforces the potential of CASGEVY to deliver durable, transformative benefits to those who have historically had limited options,” said Reshma Kewalramani, M.D., Chief Executive Officer and President, Vertex. “We’re deeply grateful to the patients, families and investigators who pa
Robinhood Chooses Morpho to Power New Earn Product1.7.2026 22:15:00 EEST | Press release
Morpho, the open blockchain-based credit network, today announced it will power Robinhood’s new Earn product, enabling Robinhood's millions of eligible users more options to earn yield onchain via a self-custody wallet, directly within the Robinhood app. The product will roll out progressively to Robinhood's US customer base over the coming weeks. The Robinhood Earn product aims to provide risk-adjusted yield on idle balances using USDG, a dollar-pegged stablecoin. Morpho serves as the underlying credit network, Steakhouse Financial curates the vault infrastructure supporting the product, and Robinhood Chain acts as the settlement layer. The product is delivered through a seamless experience in the Robinhood app. Morpho operates as an open network on the blockchain. Lenders and borrowers compete in real time, helping create more efficient markets and enabling financial products with better rates and terms for users. USDG supplied through Robinhood Earn is deposited into a Morpho Vault
Photonics Innovators Worldwide Invited to Compete for SPIE Prism Awards1.7.2026 21:33:00 EEST | Press release
SPIE, the international society of optics and photonics, invites the optics and photonics community to apply for this year’s SPIE Prism Awards, which recognize outstanding new products making waves on the market. Honorees will be announced at the highly-anticipated award ceremony on 3 February 2027 at SPIE Photonics West in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701642411/en/ SPIE Prism Awards honor exceptional new products transforming optics and photonics technologies. These awards, dubbed the “Oscars of Photonics,” provide scientists and engineers in the optics and photonics industry the opportunity to showcase their contributions to the field. Finalists and winners receive extensive print, web, and onsite promotion at SPIE Photonics West, which draws more than 22,000 researchers and industry leaders every year. “The Prism Awards are recognized across the optics and photonics industry
Around 500 Attend Sino-European ESG Conference in Germany1.7.2026 19:00:00 EEST | Press release
Around 500 government officials, business executives and academics from China and Europe gathered in the western German city of Mainz on Friday for the Third Sino-European Corporate ESG Best Practice Conference to discuss how deeper cooperation can support sustainable economic growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701255421/en/ Group photo of selected attendees at the conference. Hosted by the Chinese Consulate General in Frankfurt and jointly organized with authorities from Germany and China, the conference brought together participants from China, Germany, France, Italy, the Netherlands, Denmark, Luxembourg and several other countries under the theme "From Vision to Practice: Empowering Sustainable Growth Through Collaboration." Francesco La Camera, Director-General of the International Renewable Energy Agency (IRENA), delivered a video address. Speaking at the opening ceremony, Huang Yiyang, Chinese Co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom